| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-64796SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-235SS | |||
| Azide and BSA Free | NBP2-80597 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB100-56727 | |||
| BSA Free | NB100-56723SS | |||
| Azide and BSA Free | NB100-56727SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-80652-0.1mg | |||
| BSA Free | NB100-77417SS | |||
| Azide and BSA Free | NBP2-80652 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Allophycocyanin | NB7156APC | |||
| Biotin | NB7158 | |||
| DyLight 350 | NB7156UV | |||
| DyLight 405 | NB7156V | |||
| DyLight 488 | NB7156G | |||
| DyLight 550 | NB7156R | |||
| DyLight 594 | NB7156DL594 | |||
| DyLight 650 | NB7156C | |||
| DyLight 680 | NB7156FR | |||
| DyLight 755 | NB7156IR | |||
| FITC | NB7159 | |||
| HRP | NB7160 | |||
| Janelia Fluor 525 | NB7156JF525 | |||
| Janelia Fluor 669 | NB7156JF669 | |||
| PE | NB7156PE | |||
| PerCP | NB7156PCP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24917SS | |||
| Azide and BSA Free | NBP2-77073 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2219SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24787SS | |||
| Azide and BSA Free | NBP2-80981 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 405 | NLS1878AF405 | |||
| Alexa Fluor 488 | NLS1878AF488 | |||
| Alexa Fluor 647 | NLS1878AF647 | |||
| Alexa Fluor 700 | NLS1878AF700 | |||
| Biotin | NLS1878B | |||
| DyLight 405 | NLS1878V | |||
| DyLight 488 | NLS1878G | |||
| DyLight 550 | NLS1878R | |||
| DyLight 650 | NLS1878C | |||
| FITC | NLS1878F | |||
| HRP | NLS1878H | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-77855SS | |||
| Azide and BSA Free | NBP2-80773 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-76769SS | |||
![Immunohistochemistry-Frozen: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - Analysis using the FITC conjugate of CD31/PECAM-1 Antibody (TLD-3A12) (NB100-64796). Staining of rat brain cryosection with Mouse.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-TLD-3A12-Immunohistochemistry-Frozen-NB100-64796-img0012.jpg "Immunohistochemistry-Frozen: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - Analysis using the FITC conjugate of CD31/PECAM-1 Antibody (TLD-3A12) (NB100-64796). Staining of rat brain cryosection with Mouse.")
![Flow Cytometry: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - Analysis using the Alexa Fluor (R) 488 conjugate of CD31/PECAM-1 Antibody (TLD-3A12) (NB100-64796). Staining of PBMC's (Monocyte gate at 1 x 10^6 cells/ml) with CD31 antibody (orange) stained at a dilution of 1:500. Shown with mIgG (AF488) isotype control (blue).](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-TLD-3A12-Flow-Cytometry-NB100-64796-img0007.jpg)
![Immunohistochemistry-Paraffin: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - Analysis of CD31 in 4th day cutaneous wound section of diabetic rat using CD31/PECAM-1 Antibody (TLD-3A12). Image from verified customer review.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-TLD-3A12-Immunohistochemistry-Paraffin-NB100-64796-img0005.jpg)
![Immunohistochemistry-Frozen: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - Analysis using the FITC conjugate of CD31/PECAM-1 Antibody (TLD-3A12) (NB100-64796). Staining of rat spleen cryosection.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-TLD-3A12-Immunohistochemistry-Frozen-NB100-64796-img0013.jpg)
![Immunohistochemistry-Paraffin: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - IHC analysis for the expression of CD31 of wound tissues of different groups of rats (magnification 200). n = 6, **P less than 0.01. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/sci/2019/9564869/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-TLD-3A12-Immunohistochemistry-Paraffin-NB100-64796-img0014.jpg)
![Western Blot: BLIMP1/PRDM1 Antibody (3H2-E8) - BSA Free [NB600-235] - BLIMP1/PRDM1 Antibody (3H2-E8) [NB600-235] - The effect of IL-21 and CD40L exposure on MEC1 and MEC2 cells. Expression of EBNA-2 and LMP-1 in IL-21 treated cells. Expression of EBNA-2, LMP-1 and Blimp-1 by immunoblotting; positive control: CBM1-Ral-STO, negative control: Ramos. 1.5x105 cells were loaded in the control lanes and 5x105 were loaded in both untreated and IL-21 treated MEC1 and MEC2 lanes. Note low expression of EBNA-2 and high expression of LMP-1 after IL-21 treatment and induction of Blimp-1 after IL-21 treatment. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0106008), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/BLIMP1-PRDM1-Antibody-3H2-E8-Western-Blot-NB600-235-img0031.jpg "<b>Biological Strategies Validation. </b>Western Blot: BLIMP1/PRDM1 Antibody (3H2-E8) - BSA Free [NB600-235] - BLIMP1/PRDM1 Antibody (3H2-E8) [NB600-235] - The effect of IL-21 and CD40L exposure on MEC1 and MEC2 cells. Expression of EBNA-2 and LMP-1 in IL-21 treated cells. Expression of EBNA-2, LMP-1 and Blimp-1 by immunoblotting; positive control: CBM1-Ral-STO, negative control: Ramos. 1.5x105 cells were loaded in the control lanes and 5x105 were loaded in both untreated and IL-21 treated MEC1 and MEC2 lanes. Note low expression of EBNA-2 and high expression of LMP-1 after IL-21 treatment and induction of Blimp-1 after IL-21 treatment. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0106008), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: BLIMP1/PRDM1 Antibody (3H2-E8) [NB600-235] - A431 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton-X100. The cells were incubated with anti-BLIMP1 (3H2-E8) at 10 ug/ml overnight at 4C and detected with an anti-mouse IgG Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/BLIMP1-PRDM1-Antibody-3H2-E8-Immunocytochemistry-Immunofluorescence-NB600-235-img0028.jpg)
![Immunohistochemistry-Paraffin: BLIMP1/PRDM1 Antibody (3H2-E8) [NB600-235] - Analysis using paraffin-embedded human tonsil tissue with BLIMP1/PRDM1 antibody at dilution of 1:50. Detection is completed through VC001 (DAB) and Counterstained by hematoxylin; labeling is predominantly in germinal centers. Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/BLIMP1-PRDM1-Antibody-3H2-E8-Immunohistochemistry-Paraffin-NB600-235-img0025.jpg)
![Flow Cytometry: BLIMP1/PRDM1 Antibody (3H2-E8) - BSA Free [NB600-235] - An intracellular stain was performed on A431 cells with BLIMP1/PRDM1 Antibody (3H2-E8) NB600-235 (blue) and a matched isotype control MAB002 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (84540, Thermo Fisher).](http://images.novusbio.com/fullsize/BLIMP1-PRDM1-Antibody-3H2-E8-BSA-Free-Flow-Cytometry-NB600-235-img0032.jpg)
![Western Blot: BLIMP1/PRDM1 Antibody (3H2-E8) [NB600-235] - Detection of Blimp-1 in murine plasmacytoma cell lysate (P3X) using NB 600-235. 1881: murine pre-B cell lysate (negative control). Photo courtesy of DA Savitsky, Columbia University.](http://images.novusbio.com/fullsize/BLIMP1-PRDM1-Antibody-3H2-E8-Western-Blot-NB600-235-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: BLIMP1/PRDM1 Antibody (3H2-E8) [NB600-235] - Double IF for Blimp-1 (green) and Ki-67 (proliferation, red) with DAPI counterstain, at 10x magnification (scale bar is 10um). Positive surface epithelium and centrocytes are labelled. Photo courtesy of Dr. Giorgio Cattoretti, Institute for Cancer Genetics, Columbia University, NY.](http://images.novusbio.com/fullsize/BLIMP1-PRDM1-Antibody-3H2-E8-Immunocytochemistry-Immunofluorescence-NB600-235-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: BLIMP1/PRDM1 Antibody (3H2-E8) [NB600-235] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti-BLIMP1/PRDM1 (3H2-E8) conjugated to DyLight 550 [NB600-235R] at 20ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/BLIMP1-PRDM1-Antibody-3H2-E8-Immunocytochemistry-Immunofluorescence-NB600-235-img0027.jpg)
![Flow Cytometry: BLIMP1/PRDM1 Antibody (3H2-E8) [NB600-235] - IL-10+Blimp-1-, IL-10+Blimp-1+, IL-10-Blimp-1+ and IL-10-Blimp-1- cells, % total living single splenic CD19+ cells of 3 total mice (Tedder Lab; Duke Univ).](http://images.novusbio.com/fullsize/BLIMP1-PRDM1-Antibody-3H2-E8-Flow-Cytometry-NB600-235-img0011.jpg)
![Flow Cytometry: BLIMP1/PRDM1 Antibody (3H2-E8) [NB600-235] - Blimp-1 expression by IL-10+ (black line), IL-10- (dotted line) or CD8+ (thin, shaded line) cells (Tedder Lab; Duke Univ)](http://images.novusbio.com/fullsize/BLIMP1-PRDM1-Antibody-3H2-E8-Flow-Cytometry-NB600-235-img0013.jpg)
![Flow Cytometry: BLIMP1/PRDM1 Antibody (3H2-E8) [NB600-235] - Blimp-1 expression by CD19+ (thick black line) or CD8+ (thin, shaded line). (Tedder Lab; Duke Univ).](http://images.novusbio.com/fullsize/BLIMP1-PRDM1-Antibody-3H2-E8-Flow-Cytometry-NB600-235-img0015.jpg)
![Flow Cytometry: BLIMP1/PRDM1 Antibody (3H2-E8) [NB600-235] - Analysis using the Biotin conjugate of NB600-235. Staining of Blimp-1 in mouse spleen. Image courtesy of product review by Branislav Krljanac.](http://images.novusbio.com/fullsize/BLIMP1-PRDM1-Antibody-3H2-E8-Flow-Cytometry-NB600-235-img0024.jpg)
![Flow Cytometry: BLIMP1/PRDM1 Antibody (3H2-E8) [NB600-235] - An intracellular stain was performed on U266 cells with BLIMP1/PRDM1 Antibody (3H2-E8) NB600-235 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and permeabilized with 0.1% Saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).](http://images.novusbio.com/fullsize/BLIMP1-PRDM1-Antibody-3H2-E8-Flow-Cytometry-NB600-235-img0029.jpg)
![Flow Cytometry: BLIMP1/PRDM1 Antibody (3H2-E8) [NB600-235] - An intracellular stain was performed on A431 cells with BLIMP1/PRDM1 [3H2-E8] Antibody NB600-235C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 650.](http://images.novusbio.com/fullsize/BLIMP1-PRDM1-Antibody-3H2-E8-Flow-Cytometry-NB600-235-img0030.jpg)
![Western Blot: BLIMP1/PRDM1 Antibody (3H2-E8) - BSA Free [NB600-235] - The effect of IL-21 & CD40L exposure on MEC1 & MEC2 cells.Expression of EBNA-2 & LMP-1 in IL-21 treated cells (A, B). (A) Simultaneous immunofluorescence staining of EBNA-2 (Green) & LMP-1 (Red); magnification (×100), scale bar 25 µm. Note the downregulation of EBNA-2 & upregultion of LMP-1 after IL-21 treatment. (B) Expression of EBNA-2, LMP-1 & Blimp-1 by immunoblotting; positive control: CBM1-Ral-STO, negative control: Ramos. 1.5×105 cells were loaded in the control lanes & 5×105 were loaded in both untreated & IL-21 treated MEC1 & MEC2 lanes. Note low expression of EBNA-2 & high expression of LMP-1 after IL-21 treatment & induction of Blimp-1 after IL-21 treatment. (C) Activity of the W & C promoters that regulate EBNA-2 expression & LMP-1 mRNA expression by Q-PCR. Note the difference in EBNA-2 regulation; the MEC2 cell uses both Wp & Cp while in MEC1 only Wp is active. (D) Expression of EBNA-2 & LMP-1 in cells exposed to CD40L. Simultaneous immunofluorescence staining; for details see (A). Note: EBNA-2 & LMP-1 are downregulated by CD40L in both lines. (E) CD40L induced modulation of surface marker by FACS analysis. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0106008), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-235_mouse-monoclonal-blimp1-prdm1-antibody-3h2-e8-31020241616096.jpg)
![Western Blot: TLR4 Antibody (HTA125) [NB100-56723] - Untransfected 293T cells probed with the monoclonal antibody against TLR4 (NB100-56723, Lane 1), TLR4 transfected 293T cells probed with the TLR4 monoclonal antibody (Lane 2), and with antibodies affinity-purified against the celiac peptide (Lane 3). TLR4 transfected 293T cells probed with TLR4 monoclonal (biotin) antibody (Lane 4) and probed first with affinity-purified anti-peptide antibodies, followed by an incubation with biotin-labelled anti-TLR4 monoclonal antibody (Lane 5). Human plasmocytoid dendritic cells probed with TLR4 monoclonal antibody (Lane 6), human monocytes probed with TLR4 monoclonal antibody (Lane 7) and with affinity-purified anti-peptide antibodies (Lane 8). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pmed.0030358) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR4-Antibody-HTA125-Western-Blot-NB100-56723-img0023.jpg "Western Blot: TLR4 Antibody (HTA125) [NB100-56723] - Untransfected 293T cells probed with the monoclonal antibody against TLR4 (NB100-56723, Lane 1), TLR4 transfected 293T cells probed with the TLR4 monoclonal antibody (Lane 2), and with antibodies affinity-purified against the celiac peptide (Lane 3). TLR4 transfected 293T cells probed with TLR4 monoclonal (biotin) antibody (Lane 4) and probed first with affinity-purified anti-peptide antibodies, followed by an incubation with biotin-labelled anti-TLR4 monoclonal antibody (Lane 5). Human plasmocytoid dendritic cells probed with TLR4 monoclonal antibody (Lane 6), human monocytes probed with TLR4 monoclonal antibody (Lane 7) and with affinity-purified anti-peptide antibodies (Lane 8). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pmed.0030358) licensed under a CC-BY license.")
![Block/Neutralize: TLR4 Antibody (HTA125) [NB100-56723] - Human monocyte-derived DCs were pre-incubated wit TLR-neutralizing antibodies including TLR4 antibody (NB100-56723) for 1 h. Afterwards, DCs were infected with H. pylori G27 (MOI 5) and the levels of the costimulatory molecule CD86 and the maturation marker CD83 were analyzed by FACS on CD11c+ cells 24 h post-infection. Data are presented as mean +/- SD of five independent experiments. *p<=0.05, **p<=0.005, ***p<=0.0005. Asterisks on top of bars indicate significance relative to non-neutralized, H. pylori-primed control cells. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0104804) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR4-Antibody-HTA125-Block-Neutralize-NB100-56723-img0022.jpg)
![Flow Cytometry: TLR4 Antibody (HTA125) [NB100-56723] - Analysis using Azide/BSA FREE version of NB100-56727. Cell surface analysis of TLR4 in stable HEK293/hTLR4 cells using this antibody. Secondary antibody goat anti-mouse IgG-PE at 0.25ug/10^6 cells. Both stable HEK293/hTLR4 and HEK293/Vector cell lines were equally stained.](http://images.novusbio.com/fullsize/TLR4-Antibody-HTA125-Flow-Cytometry-NB100-56723-img0011.jpg)
![Flow Cytometry: TLR4 Antibody (HTA125) [NB100-56723] - Staining of U937 cells with mouse anti human CD284:RPE. Image using the PE form of this antibody.](http://images.novusbio.com/fullsize/TLR4-Antibody-HTA125-Flow-Cytometry-NB100-56723-img0016.jpg)
![Flow Cytometry: TLR4 Antibody (HTA125) [NB100-56723] - Analysis using Azide/BSA FREE version of NB100-56727. Staining of human peripheral blood monocytes with Mouse anti Human CD284.](http://images.novusbio.com/fullsize/TLR4-Antibody-HTA125-Flow-Cytometry-NB100-56723-img0014.jpg)
![Block/Neutralize: TLR4 Antibody (HTA125) [NB100-56723] - Validation of the neutralizing effect of this antibody on TLR4 activity. The TLR4/MD-2/CD14/IL-8 Prom/LUCPorter HeLa cells were plated in 96-well white plates at 1 x 10^5 cells/well. After 16 h, cells were preincubated with different amounts of this antibody for 1 h and then stimulated with 10 ng/ml LPS for 6 h. Luciferase activity was then directly analyzed using the one-step luciferase reporter assay reagent. Data Summary: It inhibited LPS-mediated TLR4 activity in the TLR4/MD-2/CD14/IL-8 Prom/LUCPorter cell line. Image using the Azide Free format of this antibody.](http://images.novusbio.com/fullsize/TLR4-Antibody-HTA125-Block-Neutralize-NB100-56723-img0020.jpg)
![Flow Cytometry: CD45 Antibody (30-F11) [NB100-77417] - Analysis of CD45 (30F11) in freshly isolated mouse (Balb C) splenocytes (1x10^6) were stained with [NB100-77417] at 1:1000 dilution and detected with FITC conjugated donkey anti-rat IgG secondary (orange). Shown with rat IgG isotype control (blue).](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Flow-Cytometry-NB100-77417-img0004.jpg "Flow Cytometry: CD45 Antibody (30-F11) [NB100-77417] - Analysis of CD45 (30F11) in freshly isolated mouse (Balb C) splenocytes (1x10^6) were stained with [NB100-77417] at 1:1000 dilution and detected with FITC conjugated donkey anti-rat IgG secondary (orange). Shown with rat IgG isotype control (blue).")
![Immunohistochemistry-Paraffin: CD45 Antibody (30-F11) [NB100-77417] - Analysis of FFPE section of mouse spleen using rat monoclonal CD45 antibody (30-F11) [NB100-77417] at 1:50 dilution. The antibody generated an expected membrane staining in the red and white pulp spleenocytes of the tested spleen section.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-Paraffin-NB100-77417-img0006.jpg)
![Immunohistochemistry-Paraffin: CD45 Antibody (30-F11) [NB100-77417] - Mouse glomeruli stained with CD45 antibody. 4% formaldehyde fixed paraffin sections. EDTA was used for antigen retrieval. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-Paraffin-NB100-77417-img0013.jpg)
![Immunohistochemistry: CD45 Antibody (30-F11) [NB100-77417] - Analysis of a FFPE embedded tissue section of mouse liver using 1:100 dilution of CD45 antibody (30-F11) [NB100-77417]. The signal was developed using AEC reagent based method with hematoxylin counterstaining.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-NB100-77417-img0003.jpg)
![Immunohistochemistry-Frozen: CD45 Antibody (30-F11) [NB100-77417] - Analysis of a mouse spleen cryosection using CD45 antibody (30-F11) [NB100-77417] at 1:50 dilution. The signal was detected using goat anti-rat Alexa fluor 488 secondary with DAPI counterstaining. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-Frozen-NB100-77417-img0008.jpg)
![Immunohistochemistry-Paraffin: CD45 Antibody (30-F11) [NB100-77417] - Staining of a FFPE mouse liver tissue section using 1:100 dilution of CD45 antibody (30-F11) [NB100-77417]. Signal was detected using AF488 conjugated donkey anti-rat secondary antibody at 1:500 dilution. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-Paraffin-NB100-77417-img0002.jpg)
![Immunohistochemistry: CD45 Antibody (30-F11) [NB100-77417] - Severe apoptosis and pathology in the orally infected heart. Experimental design is as outlined in Fig. 1B. Heart sections from moribund mice were examined with H&E, and immunohistochemistry staining for pan-leukocyte infiltration using an anti-CD45 antibody. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-47455-3), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-NB100-77417-img0009.jpg)
![Immunohistochemistry: CD45 Antibody (30-F11) [NB100-77417] - Severe apoptosis and pathology in the orally infected heart. Experimental design is as outlined in Fig. 1B. Heart sections from moribund mice were examined with H&E, and immunohistochemistry staining for pan-leukocyte infiltration using an anti-CD45 antibody. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-47455-3), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-NB100-77417-img0012.jpg)
![Immunohistochemistry: CD45 Antibody (30-F11) [NB100-77417] - VP1-positive infiltrating M2 macrophage and VP1-positive pneumocytes were detectable in the orally infected lung. Adjacent lung sections were examined with H&E and IHC staining for a pan-leukocyte marker CD45. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-47455-3), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-NB100-77417-img0011.jpg)
![Flow Cytometry: Goat anti-Rabbit IgG (H+L) Secondary Antibody [NB7156] - Both samples are cultured mouse microglial cells. The red is stained cells while the grey are cells with no primary antibody added (but the secondary antibody is present). Flow cytometry image submitted by a verified customer review.. Using the FITC format of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-Flow-Cytometry-NB7156-img0001.jpg "Flow Cytometry: Goat anti-Rabbit IgG (H+L) Secondary Antibody [NB7156] - Both samples are cultured mouse microglial cells. The red is stained cells while the grey are cells with no primary antibody added (but the secondary antibody is present). Flow cytometry image submitted by a verified customer review.. Using the FITC format of this antibody.")
![Flow Cytometry: TLR8 Antibody (44C143) [NBP2-24917] - Intracellular expression of TLR8 in monocyte-derived macrophages (MDMs). MDMs which were incubated with PE-conjugated anti-TLR8 or isotype antibody control. Intracellular expression was determined by flow cytometry. Representative profiles were similar in four independent experiments (n=4 subjects). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0104039) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Flow-Cytometry-NBP2-24917-img0018.jpg "Flow Cytometry: TLR8 Antibody (44C143) [NBP2-24917] - Intracellular expression of TLR8 in monocyte-derived macrophages (MDMs). MDMs which were incubated with PE-conjugated anti-TLR8 or isotype antibody control. Intracellular expression was determined by flow cytometry. Representative profiles were similar in four independent experiments (n=4 subjects). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0104039) licensed under a CC-BY license.")
![Flow Cytometry: TLR8 Antibody (44C143) [NBP2-24917] - Expression of TLR8 in Fravel, L363, OPM1, RPMI8226, XG1, and NCI-H929 as determined by flow cytometry. HCMLs were stained using an intracellular staining protocol with TLR8 antibodies followed by relevant secondary fluorescent-conjugated antibodies. Filled histograms (purple) represent the isotype controls and the open histograms (red) indicate TLR8. Data are representative for analysis of >=2 independent experiments. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0060671) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Flow-Cytometry-NBP2-24917-img0021.jpg)
![<b>Orthogonal Strategies Validation. </b>Western Blot: TLR8 Antibody (44C143) [NBP2-24917] - All the cell lines expressed mRNA for TLR8 (Figure 1) and displayed a strong expression of TLR8 protein (Figure 2). Lysates of human intestinal tissue and mouse splenocytes were used as positive controls. Beta-actin was served as loading control and was used to normalize expression levels between cells. Data are representative for analysis of >=2 independent experiments. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0060671) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Western-Blot-NBP2-24917-img0022.jpg)
![Immunohistochemistry-Paraffin: TLR8 Antibody (44C143) [NBP2-24917] - Formalin-fixed, paraffin-embedded human spleen stained with TLR8 antibody at 2 ug/ml.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Immunohistochemistry-Paraffin-NBP2-24917-img0005.jpg)
![Flow Cytometry: TLR8 Antibody (44C143) [NBP2-24917] - HEK cells expressing TLR8 were treated with ssRNA40-Alexa 546 followed by fixation, permeablization and staining for TLR8 using anti-TLR8 Alexa 488 conjugate or isotype control IgG1/Kappa Alexa 488. TLR8 detection is shown along the horizontal axis, and ssRNA40 Alexa 546 detection is shown along the vertical axis. Direct excitation (488 and 561 nm lasers) of both fluorophores (Alexa 488 and Alexa 546) allowed quantitation of cells staining positive for TLR8 (anti-TLR8-Alexa488) and cells that had taken up ssRNA40-Alexa 546. Single-stranded RNA40 binds TLR8 (flow cytometry FRET assay). A representative experiment is shown from three independent experiments with similar results. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0104039) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Flow-Cytometry-NBP2-24917-img0019.jpg)
![Western Blot: TLR8 Antibody (44C143) [NBP2-24917] - Analysis of TLR8 in human Ramos cell lysate. Goat anti-mouse Ig HRP secondary antibody and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Western-Blot-NBP2-24917-img0006.jpg)
![Simple Western: TLR8 Antibody (44C143) [NBP2-24917] - Simple Western lane view shows a specific band for TLR8 in 0.5 mg/ml of Ramos (left) and Human Spleen (right) lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. * Non-specific interaction with the 230 kDa Simple Western standard may be seen with this antibody Image from the standard format of this antibody.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Simple-Western-NBP2-24917-img0023.jpg)
![Immunohistochemistry: EGLN1/PHD2 Antibody [NB100-2219] - IHC and Immunofluorescence of wounded tissue and normal unwounded skin. Representative images for immunofluorescent staining of PHD-2 on healed wounded skin and adjacent normal unwounded skin of wild type, heterozygous K14-Cre/homozygous floxed PHD-2, and heterozygous Col1 alpha2-Cre-ER/homozygous floxed PHD-2 mice at 400x magnification. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0093373), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunohistochemistry-NB100-2219-img0015.jpg "Immunohistochemistry: EGLN1/PHD2 Antibody [NB100-2219] - IHC and Immunofluorescence of wounded tissue and normal unwounded skin. Representative images for immunofluorescent staining of PHD-2 on healed wounded skin and adjacent normal unwounded skin of wild type, heterozygous K14-Cre/homozygous floxed PHD-2, and heterozygous Col1 alpha2-Cre-ER/homozygous floxed PHD-2 mice at 400x magnification. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0093373), licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Western Blot: EGLN1/PHD2 Antibody [NB100-2219] - In vitro analysis of PHD-2 knockout and protein quantification.Western blot data for PHD-2 knockout in fibroblasts of heterozygous Col1 alpha2-Cre-ER/homozygous floxed PHD-2 mice compared to wild type mice (*p<0.05). D') Western blot data for PHD-2 knockout in keratinocytes of heterozygous K14-Cre/homozygous floxed PHD-2 mice compared to wild type mice (*p<0.05). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0093373), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Knockdown-Validated-NB100-2219-img0016.jpg)
![Immunohistochemistry-Paraffin: EGLN1/PHD2 Antibody [NB100-2219] - Analysis of an FFPE mouse lung section using 1:200 dilution of EGLN1/PHD2 antibody. The staining was developed using HRP conjugated anti-rabbit secondary antibody and DAB reagent. The antibody generated a specific staining in the cytoplasm and nuclei of alveolar as well as bronchiolar epithelial cells. Cytoplasmic staining was observed in almost all cells while the nuclear positivity was seen in a subset of cells only.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunohistochemistry-Paraffin-NB100-2219-img0014.jpg)
![Western Blot: EGLN1/PHD2 Antibody [NB100-2219] - Detection of EGLN1/PHD2 in mouse kidney lysate. ECL exposure, 20 seconds.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Western-Blot-NB100-2219-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: EGLN1/PHD2 Antibody [NB100-2219] - EGLN1/PHD2 antibody at 1:500 in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2219-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: EGLN1/PHD2 Antibody [NB100-2219] - Analysis of EGLN1/PHD2 in ARPE-19 cells using anti-PHD2 antibody. ICC/IF image submitted by a veriifed customer review.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2219-img0009.jpg)
![Immunohistochemistry: EGLN1/PHD2 Antibody [NB100-2219] - Staining of renal tubular epithelium in mouse using NB100-2219 at 2.5 ug/mL.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunohistochemistry-NB100-2219-img0010.jpg)
![Immunohistochemistry-Paraffin: TLR5 Antibody (19D759.2) [NBP2-24787] - Analysis of FFPE tissue section of normal human skin using 5 ug/ml concentration of TLR5 antibody (clone 19D759.2). Intense membrane staining of TLR5 was observed specifically in the pigmented basel cells of epidermal layer [10X Magnification]](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Immunohistochemistry-Paraffin-NBP2-24787-img0005.jpg "Immunohistochemistry-Paraffin: TLR5 Antibody (19D759.2) [NBP2-24787] - Analysis of FFPE tissue section of normal human skin using 5 ug/ml concentration of TLR5 antibody (clone 19D759.2). Intense membrane staining of TLR5 was observed specifically in the pigmented basel cells of epidermal layer [10X Magnification]")
![<b>Biological Strategies Validation. </b>Flow Cytometry: TLR5 Antibody (19D759.2) [NBP2-24787] - Analysis using the PE conjugate of NBP2-24787. Staining of CD14-/CD83+/TLR5+ diffferentiated myeloid dendritic cells (mDCs). PBMCs were stimulated 5 days with GM-CSF+IL4 prior to the staining. The cells were stained for surface markers CD14 and CD83 FITC, and TLR5 PE. CD14- cells were gated and stained with PE-conjugated isotype control (mouse IgG2a), and FITC-conjugated CD83 (left). CD14- cells were gated and stained with 1 ug PE-conjugated TLR5 , and FITC-conjugated CD83 (right).](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Flow-Cytometry-NBP2-24787-img0011.jpg)
![Western Blot: TLR5 Antibody (19D759.2) [NBP2-24787] - BEAS-2B cells whole cell lysate. Image from verified customer review.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Western-Blot-NBP2-24787-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: TLR5 Antibody (19D759.2) [NBP2-24787] - Staining using in-vitro cultured fixed non-permeabilized MCF7 breast cancer cells (ATCC). EpCAM (cell membrane) staining is represented in green (FITC filter), nuclei staining is represented in blue (DAPI filter). Image from a verified customer review using the Alexa Fluor 488 conjugated format of this antibody.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Immunocytochemistry-Immunofluorescence-NBP2-24787-img0012.jpg)
![Immunohistochemistry: TLR5 Antibody (19D759.2) [NBP2-24787] - TLR5 and TLR7 expression in nasopharyngeal carcinoma and in the normal epithelium. Mild positive TLR5 expression in NK-U. Strong positive TLR5 expression in KSCC. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5816-9), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Immunohistochemistry-NBP2-24787-img0013.jpg)
![Flow Cytometry: TLR5 Antibody (19D759.2) - BSA Free [NBP2-24787] - Flow analysis of TLR5 in mouse MC38 cells. Image from verified customer review.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-BSA-Free-Flow-Cytometry-NBP2-24787-img0014.jpg)
![Immunohistochemistry-Paraffin: TLR5 Antibody (19D759.2) [NBP2-24787] - Human skin stained with TLR5 antibody (5 ug/ml), peroxidase-conjugate and DAB chromogen.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Immunohistochemistry-Paraffin-NBP2-24787-img0004.jpg)
![Immunohistochemistry-Paraffin: TLR5 Antibody (19D759.2) [NBP2-24787] - Analysis of TLR5 in FFPE mouse brain tissue using TLR5 antibody at 5 ug/ml.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Immunohistochemistry-Paraffin-NBP2-24787-img0002.jpg)
![Flow Cytometry: TLR5 Antibody (19D759.2) [NBP2-24787] - Intracellular flow analysis of TLR5 in human monocytes using 0.5 ug of TLR5 antibody. Shaded histogram represents cells without antibody; green represents isotype control; red represents TLR5 antibody. this antibody secondary antibody was used in this test.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Flow-Cytometry-NBP2-24787-img0003.jpg)
![Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Immunoblot of FPR2 protein in various parts of the rat brain including olfactory bulb (OB), prefrontal cortex (PFC), primary somatosensory cortex (CTX1), parietal association cortex and secondary auditory cortex (CTX2), striatum (STR), thalamus and hypothalamus (THA), hippocampus (HPC), cerebellum (CB), brainstem (BS), cervical spinal cord [SC(C)], thoracic spinal cord [SC(T)], and lumbar spinal cord [SC(L)]. Blots incubated with antigen-absorbed antibody i. e. peptide competition, show reduced band intensities. Image collected and cropped by Citeab from the following publication (Localisation of Formyl-Peptide Receptor 2 in the Rat Central Nervous System and Its Role in Axonal and Dendritic Outgrowth. Neurochem Res (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Western-Blot-NLS1878-img0012.jpg "Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Immunoblot of FPR2 protein in various parts of the rat brain including olfactory bulb (OB), prefrontal cortex (PFC), primary somatosensory cortex (CTX1), parietal association cortex and secondary auditory cortex (CTX2), striatum (STR), thalamus and hypothalamus (THA), hippocampus (HPC), cerebellum (CB), brainstem (BS), cervical spinal cord [SC(C)], thoracic spinal cord [SC(T)], and lumbar spinal cord [SC(L)]. Blots incubated with antigen-absorbed antibody i. e. peptide competition, show reduced band intensities. Image collected and cropped by Citeab from the following publication (Localisation of Formyl-Peptide Receptor 2 in the Rat Central Nervous System and Its Role in Axonal and Dendritic Outgrowth. Neurochem Res (2018)) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Mouse J774A.1, mouse reticulum cell sarcoma macrophage cell line. Left panel is + Anti-Rabbit FITC; middle panel indicates the cell nuclei stained with Hoechst; the right panel is a merged image. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NLS1878-img0008.jpg)
![Immunohistochemistry-Paraffin: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - SPM receptors differentially expressed on endothelium and infiltrating leukocytes AE](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NLS1878-img0011.jpg)
![Flow Cytometry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Flow Cytometry: [Alexa Fluor® 700] [NLS1878AF700] - Mouse splenocytes. Cells were pre-gated with live/dead and FSC-A/W to exclude dead cells and cell doublets. Image from verified customer review. Image using the Alexa Fluor 700 form of this antibody.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Flow-Cytometry-NLS1878-img0007.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Murine neutrophils were extracted from the bone marrow of C57BL/6 mice and exposed to normal glucose (90 mg/dl) or high glucose (300 mg/dl) and the expression of FPR2 was assessed by western blotting after 1, 2, or 3 hr exposure to glucose. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35112667/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FPRL1-FPR2 Antibody - BSA Free-Western Blot-NLS1878-img0013.jpg)
![Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Analysis in HL-60 cell lysate.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Western-Blot-NLS1878-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Antibody was tested in Raw264.7 cells with DyLight 488 (green). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NLS1878-img0005.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Analysis in human kidney cancer using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunohistochemistry-NLS1878-img0006.jpg)
![Electron Microscopy: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c=50A nm, e=100A nm. Image collected and cropped by Citeab from the following publication (Localisation of Formyl-Peptide Receptor 2 in the Rat Central Nervous System and Its Role in Axonal and Dendritic Outgrowth. Neurochem Res (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Electron-Microscopy-NLS1878-img0010.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-310202415382420.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-31020241534335.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-31020241534380.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-310202415382435.jpg)
![Immunocytochemistry/ Immunofluorescence: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Lipoxin A4, along with its precursors & ligand, were altered by hAECs. (A): Expression of the lipoxin A4 precursor genes ALOX‐5, ‐12, & ‐15 was increased at days 5 & 7 compared with saline controls (ALOX‐5: 0.393 ± 0.114 vs. 3.777 ± 1.98; ALOX‐12: 0.484 ± 0.248 vs. 1.520 ± 0.203; ALOX‐15: 0.020 ± 0.007 vs. 1.998 ± 0.983). ∗, p < .05. (B): Lipoxin A4 protein levels were elevated in lung lysates at day 7 in animals treated with hAECs compared with controls (0.103 ± 0.021 ng/ml vs. 0.249 ± 0.072 ng/ml, respectively). ∗, p < .05. (C): At day 7, bleomycin challenge resulted in positively stained F4/80/FPR2 cells, which were was elevated in mice treated with hAECs compared with control mice (5.720% ± 0.587% vs. 8.795% ± 0.687%, respectively). ∗, p < .05. (D): Representative images of F4/80‐ & FPR2‐positive‐stained lung sections from hAEC‐treated animals. Magnification: ×200. Scale bar =100 μm. Abbreviations: DAPI, 4′,6‐diamidino‐2‐phenylindole; FPR2, N‐formyl peptide receptor 2; hAEC, human amnion epithelial cell. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28371562), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-310202416114742.jpg)
![Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Higher expression of Fpr2 in the livers of female mice is related with hepatocyte protection.a qRT-PCP analysis for Fpr2 expression in primary hepatocytes (pHEPs) from WT (male n = 2, female n = 2) & KO mice (male n = 2, female n = 2). Total eight mice were employed in each hepatocyte isolation, & the experiments were replicated at least three times & the mean ± S.E.M. results are graphed (*p < 0.05, **p < 0.005 vs WT male-pHEPs). b Western blot analysis & c double immunofluorescent images of Fpr2 (red) with albumin (green) in these cells. Gapdh was used as internal control. DAPI (blue) was used as nuclear counterstaining. Data shown represent one of three experiments with similar results (Scale bar, 20 μm). d qRT-PCR analysis for Fpr2 & glucose-6-phosphatase (G6pc) in, e cell viability of, & f western blot analysis of cleaved Caspase-3 & pro Caspase-3 in WT & KO female mice-isolated pHEPs treated with vehicle (Veh) or 250 μM of palmitate (PA). The data shown represent one of three experiments with similar results. The mean ± S.E.M. results obtained from three repetitive experiments are graphed (*p < 0.05, **p < 0.005 vs WT-Veh). Gray circles represent individual data points. See Supplementary Data for statistical details. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35102146), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-3102024161228.jpg)
![Dual RNAscope ISH-IHC: HLA-DR Antibody (L243) [NB100-77855] - Formalin-fixed paraffin-embedded tissue sections of human metastatic tonsil were probed for HLA-DR mRNA (ACD RNAScope probe, catalog # 475891; Fast Red chromogen, ACD catalog # 322500). Adjacent tissue section was processes for immunohistochemistry using mouse monoclonal (Novus catalog # NB100-77855) at 1:50 dilution for 1 hour at room temperature followed by incubation with the anti-mouse IgG VisUCyte HRP Polymer Antibody (Catalog # VC001) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Dual-RNAscope-ISH-IHC-NB100-77855-img0016.jpg "<b>Orthogonal Strategies Validation. </b>Dual RNAscope ISH-IHC: HLA-DR Antibody (L243) [NB100-77855] - Formalin-fixed paraffin-embedded tissue sections of human metastatic tonsil were probed for HLA-DR mRNA (ACD RNAScope probe, catalog # 475891; Fast Red chromogen, ACD catalog # 322500). Adjacent tissue section was processes for immunohistochemistry using mouse monoclonal (Novus catalog # NB100-77855) at 1:50 dilution for 1 hour at room temperature followed by incubation with the anti-mouse IgG VisUCyte HRP Polymer Antibody (Catalog # VC001) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue).")
![<b>Orthogonal Strategies Validation. </b>Western Blot: HLA-DR Antibody (L243) [NB100-77855] - Analysis of human spleen (A) and human tonsil (B) tissue using HLA-DR antibody at 2 ug/mL.](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Western-Blot-NB100-77855-img0002.jpg)
![Immunohistochemistry-Paraffin: HLA-DR Antibody (L243) [NB100-77855] - Staining of HLA-DR in human spleen using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Immunohistochemistry-Paraffin-NB100-77855-img0003.jpg)
![Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the FITC conjugate of NB100-77855. Staining of Human peripheral blood lymphocytes with L243 FITC.](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Flow-Cytometry-NB100-77855-img0015.jpg)
![Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Human peripheral blood lymphocytes stained with L243 PE](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Flow-Cytometry-NB100-77855-img0001.jpg)
![Flow (Cell Surface): HLA-DR Antibody (L243) [NB100-77855] - Analysis using the Azide Free version of NB100-77855. Staining of HLA-DR expression by 5x10^5 BDCM cells using 0.5 ug of (red) and 0.5 ug of isotype control (green). This antibody and an anti-mouse IgG PE conjugated secondary antibody were used.](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Flow-Cell-Surface-NB100-77855-img0010.jpg)
![Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the PerCP/Cy5.5 conjugate of NB100-77855. Staining of HLA-DR expression by 5x10^5 human PBMC using 10 uL (0.25 ug) of this antibody. Cell surface flow kit was used for this test. Left panel shows the monocyte gate, right panel shows the lymphocyte gate.](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Flow-Cytometry-NB100-77855-img0011.jpg)
![Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the Alexa Fluor (R) 700 conjugate of NB100-77855. Staining of HLA-DR protein in human PBMCs using HLA-DR antibody [clone L243; conjugated to Alexa Fluor (R) 700] at 1:100 with 25 minutes incubation at 4C in 2% human serum, 0.5 mM EDTA in DPBS. Image from verified customer review.](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Flow-Cytometry-NB100-77855-img0012.jpg)
![Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the Biotin conjugate of NB100-77855. Staining of Human peripheral blood lymphocytes with biotinylated L243, followed by Sav-PE.](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Flow-Cytometry-NB100-77855-img0013.jpg)
![Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the DyLight 405 conjugate of NB100-77855. Staining of HLA-DR in human PBMCs using anti-HLA-DR antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Flow-Cytometry-NB100-77855-img0014.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - Validation with PD-L1 siRNA Knockdown. HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2). Loading: 10 ug of HeLa whole cell lysates per lane. Antibodies: NBP1-76769 (2 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Knockdown-Validated-NBP1-76769-img0024.jpg "<b>Genetic Strategies Validation. </b>Western Blot: PD-L1 Antibody [NBP1-76769] - Validation with PD-L1 siRNA Knockdown. HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2). Loading: 10 ug of HeLa whole cell lysates per lane. Antibodies: NBP1-76769 (2 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.")
![<b>Independent Antibodies Validation and Genetic Strategies Validation.</b>Western Blot: PD-L1 Antibody [NBP1-76769] - Independent Antibody Validation (IAV) via Protein Expression ProfileLoading: 15 ug of lysates per lane.Antibodies: NBP1-76769 (2 ug/mL), PD-L1 (2 ug/mL), and beta-actin (1 ug/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit and or anti-mouse IgG HRP conjugate at 1:10000 and 1:5000 dilution, respectively.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0023.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - CD274 (PD-L1) expression in the HNSCC patients from the TCGA database , HNSCC tissue samples and the HNSCC cells. Immunostaining of PD-L1 obtained from HNSCC tumor cells, immune cells and tumor margin tissues in HNSCC tissue samples (magnification A-200, scale bars 50AI1/4m) : low tumor staining; moderate tumor staining; high tumor staining have been observed. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-Negative-NBP1-76769-img0025.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - PD-L1 expression was evaluated in gastric cancer cells. Levels of PD-L1 protein were assessed in normal human gastric epithelial cells and 8 gastric cancer cell lines by Western blots. Image collected and cropped by Citeab from the following publication (Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Cancer Res (2019)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0026.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: PD-L1 Antibody [NBP1-76769] - Upregulated expression of PD-L1 in cisplatin-resistant cells through IL-6/STAT3. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0027.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - CD274 (PD-L1) expression in the HNSCC patients from the TCGA databas HNSCC cells. CD274 expression with survival and its relation with therapy in the HNSCC patients from the TCGA database. Expression of CD274 gene and PD-L1 protein in the established cisplatin-resistant HNSCC cells and cisplatin sensitive cells by qRT-PCR and WB (F, H): CD274 (PD-L1) expressed in cisplatin resistant cell. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0028.jpg)
![Immunocytochemistry/Immunofluorescence: PD-L1 Antibody [NBP1-76769] - U-251 MG cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP1-76769 at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-76769-img0029.jpg)
![Flow Cytometry: PD-L1 Antibody [NBP1-76769] - An intracellular stain was performed on U-251 MG cells with PD-L1 Antibody NBP1-76769 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NBP1-76769-img0030.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - Expression of CD274 in Human melanoma SK-MEL-28 cell line upon treatment with 200 mM ethanol. Dilution: 1:1,000 in PBS with 5% BSA. Secondary Ab: anti-Rabbit IgG 1:5,000. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0019.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Human tonsil tissue with PD-L1 antibody at 5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0017.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - Staining of human heart tissue with antibody at 2.5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0010.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - PD-L1/B7-H1 Antibody [NBP1-76769] - PD-L1 in rat heart tissue with at 5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0020.jpg)
![Flow Cytometry: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Analysis of A-20 cells using B7-H1/PD-L1/CD274 antibody at 0.5 ug/mL. Green: Isotype control. Red : B7-H1/PD-L1/CD274 antibody.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NBP1-76769-img0018.jpg)
![Immunofluorescence: PD-L1 Antibody [NBP1-76769] - Human Heart cells with PD-L1 antibody at 20 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunofluorescence-NBP1-76769-img0009.jpg)
![Dual RNAscope ISH-IHC: PD-L1 Antibody [NBP1-76769] - PDCD1 mRNA (red) and PD-L1 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human lung cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-PDCD1 and PD-L1 antibody at 1:100 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Dual-RNAscope-ISH-IHC-NBP1-76769-img0031.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ROS mediated PD-L1 upregulation in FFA-treated LO2 cells. (a) Intracellular ROS in LO2 cells before & after FFA treatment measured by DCFH-DA. (b–d) Expression levels of NOX2 & NOX4 measured using qRT-PCR & western blot. (e) JC-1 probes were used to detect mitochondrial membrane potential. (f–j) Intracellular ROS in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment, measured by DCFH-DA, PD-L1 expression determined by western blot. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415382415.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-31020241534538.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 expression levels in liver samples & FFA-treated LO2 cells. (a–d) PD-L1 expression & CD8+ T cells in the liver tissues determined by immunohistochemistry. (e) Intracellular lipid accumulation after FFA treatment (0.8 mM) for 24 hour measured by Oil Red staining. (f–i) Expression levels of PD-L1 detected by qRT-PCR, western blot, & immunofluorescence. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415175299.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415291978.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415175210.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ROS/ZNF24/PD-L1 pathway activation in NAFLD models. (a) Intracellular ROS in hepatocytes in NAFLD significantly increased. (b) JC-1 probes were used to detect mitochondrial membrane potential. (c & d) NOX4 & ZNF24 expressions were determined by immunohistochemistry. (e & f) ROS/ZNF24/PD-L1 pathway activation examined by western blot. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415284517.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 limits liver injury in NAFLD models. (a & b) Western blot determined the effect of siRNA against PD-L1. (c) After PD-L1 knockdown, mRNA expression levels of markers of T cell activation measured by qRT-PCR. (d & e) Hepatocyte injury was evaluated by the Tunel assay & ALT/AST measurement. (f) Graph illustrating that both ROS/ZNF24 pathway activation & UBE2I-mediated ZNF24 sumoylation suppression induced by FFA promoted PD-L1 expression. ∗P < 0.05, ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-31020241529331.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 knockdown aggravated the damage of CD8 + T cells to FFA-treated LO2 cells. (a & b) Western blot determined the effect of siRNA against PD-L1. Coculturing of FFA-treated LO2 cells & CD8 + T cells in vitro. (c) mRNA expression levels of markers of T cell activation measured by qRT-PCR, (d) LO2 cell injury was evaluated by LDH assay, (e) AST or ALT in the supernatants measured by commercial assay kits. # represents that CD8 + T cells were incubated separately with LO2 cells, but supernatants were put together. ∗P < 0.05, ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415304228.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Upregulated expression of PD‐L1 in cisplatin‐resistant cells through IL‐6/STAT3. The cisplatin resistant CAL27cis & Detroit‐562cis cells had increased IL‐6 mRNA & IL‐6 protein production compared to parental cells by qRT‐PCR & ELISA (A, B). CAL27cis & Detroit‐562cis were cultured with IL‐6 (10 ng/mL, human recombinant IL‐6, R&D Systems, Minneapolis, USA) for 48 h (C). An anti‐human IL‐6 polyclonal antibody (R&D Systems, Minneapolis, USA) was used to neutralize the biological activities of IL‐6 (E, F). To inhibit signal transduction, CAL27cis & Detroit‐562cis cells were pre‐incubated for 1 h with STAT3 inhibitor V (Sigma‐Aldrich, Germany, 500 nmol/L), & then incubated with recombinant human IL‐6 (10 ng/mL) for 24 h before analysis. Data are shown as mean ± SD of 3 independent triplicate cultures (A, B, D, E, F, H). *P < .05, **P < .01 & ***P < .001, compared with the results of control without IL‐6 (D), control IgG (E, F) & with IL‐6 alone (H) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29761938), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175266.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ZNF24 promoted PD-L1 expression through binding to its promoter in FFA-treated LO2 cells. (a) A schematic of the target sites (wild & mutant) of ZNF24 in the promoter of PD-L1. (b–d) Dual-luciferase reporter assays performed in LO2 cells transfected with WT or MT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression. (e–g) ZNF24 expression after FFA treatment determined by qRT-PCR & western blot. (h & i) ZNF24 expression in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment, measured by western blot. (j & k) ZNF24 & PD-L1 expression in LO2 cells pretreated with siRNA against ZNF24, followed by FFA treatment detected by western blot. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416165623.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - LfcinB reduced IL‐6‐dependent PD‐L1 expression in cisplatin‐resistant HNSCC cells (A‐C) & inhibited the xenograft growth from CAL27cis & Detroit‐562cis (D, E). The markedly decreased IL‐6 (A) by ELISA & PD‐L1 by WB (B, C) in the acquired cisplatin‐resistant cells were detected. In figure A, C & D, data are shown as mean ± SD of 3 independent triplicate cultures. *P < .05 & **P < .01, compared with the results of control without IL‐6 (A, C). To investigate the effects of LfcinB on in vivo growth of CAL27cis & Detroit‐562cis, we treated nude mice carrying CAL27cis (D) & Detroit‐562cis (E) xenografts with once‐daily injection of 0.75 mg LfcinB (n = 5). Tumor growth of HNSCC xenografts displayed significant reduction after 3 days of LfcinB treatment, compared to control with saline (*P < .05 for LfcinB) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29761938), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175227.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Identification of ZNF24–UBE2I protein interactions. (a & b) Analysis of protein interactions between ZNF24 & UBE2I using the BioGRID database, further confirmed by Co-IP assays. (c–f) UBE2I expression in LO2 cells treated by FFA or pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment measured by western blot. (g & h) After FFA treatment, Sumo-1: ZNF24 & ZNF24 expression levels detected by western blot. (i & j) After UBE2I overexpression, Sumo-1: ZNF24, ZNF24, PD-L1, & UBE2I expression levels were determined by western blot. (k–m) Dual-luciferase reporter assays performed in LO2 cells transfected with WT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression with or without Sumo-1 overexpression. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175269.jpg)
![Immunohistochemistry-Paraffin: CD3 Antibody (SP7) [NB600-1441] - FFPE human tonsil stained with CD3 antibody.](http://images.novusbio.com/fullsize/CD3-Antibody-SP7-Immunohistochemistry-Paraffin-NB600-1441-img0001.jpg "Immunohistochemistry-Paraffin: CD3 Antibody (SP7) [NB600-1441] - FFPE human tonsil stained with CD3 antibody.")
![Immunohistochemistry-Frozen: CD3 Antibody (SP7) [NB600-1441] - T-cells and microglia in mouse spinal cord with acute EAE. Mouse was perfused with 4% paraformaldehyde. Spinal cord was post-fixed overnight, followed by cryoprotection with 30% sucrose for 24h. Spinal cord sections were treated with antigen-retrieval buffer (pH 6.0) at 60C for 10 min, then cooled down to room temperature (this step should not be omitted). Anti-CD3 antibody was diluted at 1:200. Incubation: room temperature overnight. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD3-Antibody-SP7-Immunohistochemistry-Frozen-NB600-1441-img0002.jpg)
![<b>Genetic Strategies Validation. </b>Immunohistochemistry-Paraffin: CD3 Antibody (SP7) [NB600-1441] - Mouse lung tissue stained against C3aR normal conditions (left) and knockdown conditions (right). IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD3-Antibody-SP7-Immunohistochemistry-Paraffin-NB600-1441-img0003.jpg)